Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Clinical Therapeutics

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting children.
• Infliximab (IFX) is a biologic therapy used for moderate to severe UC.
• Evaluating IFX efficacy and safety in pediatric UC is crucial.

Purpose of the Study:

• To assess the clinical response to infliximab (IFX) in children with acute and chronic active ulcerative colitis (UC).
• To determine the rates of colectomy and adverse events associated with IFX treatment in this pediatric population.

Main Methods:

• Retrospective chart review of pediatric UC patients treated with IFX across three centers.
• Data collection included clinical symptoms, biochemical markers, concurrent medications, colectomy status, and adverse events.
• Study duration was a median of 15 months post-first IFX infusion.

Main Results:

• Forty-five pediatric UC patients were included (median age at diagnosis 12 years).
• Cumulative 1- and 2-year colectomy risks were 21% and 26%, respectively.
• Forty-six percent of patients experienced adverse events, mostly mild infusion reactions; 7% had serious events.

Conclusions:

• Infliximab (IFX) demonstrates efficiency in preventing colectomy in pediatric patients with ulcerative colitis (UC).
• The observed risk of requiring systemic corticosteroids was lower compared to other studies.
• Adverse events associated with IFX treatment in children were predominantly mild to moderate and self-limiting.